Document Library

Filter by country
Africa
Angola
Benin
Burkina Faso
Burundi
Cameroon
Central African Republic (the)
Chad
Comoros (the)
Congo (the)
Cote d'Ivoire
Congo, DR
Eritrea
Ethiopia
The Gambia
Ghana
Guinea-Bissau
Guinea
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mozambique
Niger
Nigeria
Rwanda
Sao Tome and Principe
Senegal
Sierra Leone
South Sudan
Tanzania, UR
Togo
Uganda
Zambia
Zimbabwe
South-East Asia
Bangladesh
Bhutan
Korea, DPR
India
Myanmar
Nepal
Sri Lanka
Timor Leste
Americas
Cuba
Haiti
Honduras
Nicaragua
Bolivia
Guyana
Europe
Albania
Armenia
Azerbaijan
Bosnia-Herzegovina
Georgia
Kyrgyzstan
Moldova
Tajikistan
Turkmenistan
Ukraine
Uzbekistan
Western Pacific
Cambodia
China
Indonesia
Kiribati
Lao PDR
Mongolia
Papua New Guinea
Solomon Islands
Vietnam
Eastern Mediterranean
Afghanistan
Djibouti
Pakistan
Somalia
Sudan (the)
Yemen

06a Amendment and utilisation of the European Investment Bank EIB Frontloading Facility pdf




Board- 2026-Mtg- 02-Doc 06a 1
Report to the Board
1 -2 July 2026

Subject Amendment and utilisation of the European Investment Bank
(EIB) Frontloading Facility
Agenda item 06 a
Category For Decision

Executive Summary
The purpose of this paper is to request that the Gavi Board ratify the amendment to
the European Investment Bank (EIB) Frontloading Facility executed in December
2025 and approve the potential utilisation of up to EUR 500 million under the Facility.
The Facility is a core pillar of Gavi’s innovative finance toolkit, enabling the Alliance
to convert donor commitments into immediate impact and protecting programme
delivery in a period of heightened fiscal uncertainty . Building on a strong track
record, including a EUR 600 million facility deployed in 2022 and repaid, the
instrument provides predictable, just‑in ‑ time liquidity to support market shaping,
safeguard core programmes, and ensure rapid response capacity for health
emergencies. The December 2025 amendment extends the availability of the
Facility through 2026 with limited technical changes, preserving acc ess to this
proven financing tool at a critical time. The proposed drawdown authorisation of up
to EUR 500 mil lion provides flexibility to respond to evolving liquidity needs, with
utilisation phased based on operational requirements. These proposals were
reviewed by the Audit and Finance Committee at its May 2026 meeting, which
recommended approval to the Board.
Action Requested of the Board
The Gavi Alliance Audit and Finance Committee recommends to the Gavi Alliance
Board that it:

a) Approve the ratification of the amendment to the European Investment Bank
(EIB) Frontloading Facility executed by the Chief Executive Officer in December
2025 as set out in Annex B to Doc 06a ; and

b) Approve the utilisation of the EIB Frontloading Facility through drawdowns of up
to EUR 500 million, subject to satisfaction of all conditions precedent.
Next steps/timeline
Subject to Board approval and satisfaction of all conditions precedent, the
Secretariat will operationalise the Facility and execute drawdowns as required
based on liquidity needs.

06a Annex A Implications and anticipated impacts pdf




Board- 2026-Mtg- 02-Doc 06a-Annex A 1
Report to the Board
1 -2 July 2026

Annex A: Implications and anticipated impact s
• Risk implication and mitigation, including information on the risks of inaction
- The extension of EIB’s Facility provides Gavi with a critical fundraising and
liquidity management tool.
- Absent this extended Facility , Gavi risks not being prepared to adapt to donor
budgetary constraints or having necessary liquidity to respond to emerging
needs in 2026 .
- As the Facility is the only frontloading facility for direct grants currently available,
without the amendment Gavi risk s being unprepared to respond to the evolution
of financing needs.
- As the amendment is focused on select key terms, the Secretariat’s
assessment is that the amendment does not increase any risks compared to
prior EIB frontloading agreements .
- The use of EIB funds requires robust functions to operationalise the facility,
absent which Gavi could be subject to operational risks .
- The Facility is intended to be leveraged for Gavi’s needs as well as serve as an
important source of surge liquidity; should utilisation not materialise there could
be risks to Gavi’s reputation with financing partners or donors related to the
value or eff ectiveness of financing instruments .
• Impact on countries
- N/A
• Impact on Alliance
- N/A
• Legal and governance implications
- In accordance with Gavi’s Delegation of Authority Policy, financing
arrangements under which Gavi assumes liabilities in excess of US$ 50 million
requires prior recommendation by the Audit and Finance Committee and
approval by the Board. The current approval would serve as the necessary
approval for the Secretariat to undertake one or more drawdowns of the Facility
up to EUR 500 million in aggregate.



06a Annex B Summary of key terms pdf




Board- 2026-Mtg- 02-Doc 06a-Annex B 1
Report to the Board
1 -2 July 2026

Annex B: Summary of key terms
Term Details
Facility Size EUR 1,000,000,000
Drawdown Period 12 months from Amendment Deed (extended 1 year through 2026)
Tranche Size Min. EUR 40m, up to 10 tranches per credit
Tranche Maturity 18 months to 6 years from disbursement (prepayable if needed)
Interest Rate
Floating EURIBOR for EUR drawdown + spread (spread set at time of
EIB offer per tranche)
ο Indicative for April 2026:
 1.5y bullet : Euribor 3M (2. 15%) + 37.8 bps
 3y bullet : Euribor 3M (2. 15%) + 37.6 bps
 6y bullet : Euribor 3M (2. 15%) + 48.9 bps
Interest Payment Semi -annual (11 March, 11 September)
Non -Utilisation Fee Concessional rate on undrawn balance (expiry of a waiver of the
non -utilisation fee in the original Facility)
Use of Proceeds Vaccines, equipment, up to 3% for operations
Security Pledged donations and accounts

06b African Vaccine Manufacturing Accelerator AVMA pdf




Board- 2026-Mtg- 02-Doc 06b 1
Report to the Board
1 -2 July 2026

Subject African Vaccine Manufacturing Accelerator (AVMA)
Agenda item 06b
Category Decision

Executive Summary
The African Vaccine Manufacturing Accelerator (AVMA) was approved by the Gavi
Board in December 2023 and launched in June 2024 as a ten- year, US$ 1 billion
pull- financing instrument to support commercially sustainable vaccine
manufacturing in Africa. Eight een months in, AVMA is delivering against its design:
the first milestone disbursement is envisaged in late 2026; eight African-
manufactured vaccine products are on a credible pathway to WHO prequalification;
thirteen technology transfers are underway acro ss six African countries; and
approximately US$ 3 billion in complementary ecosystem financing has been
mobilised since launch. AVMA attracted pledges of approximately US$ 189 million
above the Board-approved US$ 1 billion ceiling, which require a Board decision
before they can be deployed. Following guidance from the October 2025
Programme and Policy Committee (PPC) and the December 2025 Board, the
Secretariat developed proposals for programming the additional pledges in
consultation with AVMA investors, m anufacturers, partners, and African Union
constituencies. The proposals were considered by the PPC at its meeting in May
2026. The PPC recommended to the Board the establishment of two new windows
within AVMA — a Vaccine Buy -Down Window covering Gavi’s costs for AVMA-
e ligible vaccines (not including country co- financing), and a one- off Ecosystem
Support Window. The PPC also recommended an accelerated, narrow Course
Correction to AVMA’s key terms in advance of the planned, regular 2027 Course
Correction, to take account of the changed operating context since AVMA’s launch
in 2024. Separately, following the World Health Organization’s declaration on
17 May 2026 of a Public Health Emergency of International Concern (PHEIC) in
respect of the outbreak of Ebola, the CEO proposes immediately amending AVMA’s
key terms to allow Afr ican-manufactured vaccines approved under WHO
Emergency Use Listing (EUL) to be designated a Priority Vaccine under AVMA .
Action Requested of the Board
The Gavi Alliance Programme and Policy Committee (PPC) recommends to the
Gavi Alliance Board that it:

a) Approve the programming of the additional US$ 189 million in African Vaccine
Manufacturing Accelerator (AVMA) pledges above the Board- approved
US$ 1 billion ceiling in support of a time- limited addendum to the AVMA key
terms as set out in Annex A to Doc 06b, known as “AVMA+”;

06b Annex A AVMA and Addendum to Key Terms pdf



Board-2026-Mtg -02-Doc 06b-Annex A 1
Report to the Board
1-2 July 2026
Annex A: AVMA+ Addendum to Key Terms
This Annex provides an updated overview of key terms of the AVMA approved by the
Gavi Board Board- 2024-Mtg -02- Doc 11b- Annex A: AVMA Base Proposal, which
themselves were updated from Board- 2023-Mtg-04- Doc 10b - Annex A: AVMA Key
Terms.
2026 Proposed updates are shown in bold underline and are restricted to the
acceptance of EUL for vaccines against Bundibugyo virus disease (BVD), and
components to be considered by the July 2026 Board, proposals known as AVMA+.
Core Terms
Design
element
Details


Size Funding requirement of US$ 750-
1,000 million – with the upper end of the
range set to accommodate an ambitious outcome for African products in
terms of number of incentivised manufacturers and their commercial
volumes

Scope All Gavi Alliance supported vaccines (with differences in payments, see
“Incentives”), fill & finish
-only (i.e. drug product), and “end -to - end” drug
substance + drug product.

Duration To be
launched in June 2024 with a proposed duration of 10 years (payments can continue for a period beyond the 10- year mark, depending
on tender lengths)

Eligibility

Vaccine Type: Qualifying Vaccine that is WHO Prequalified (or, in the case of
a vaccine for Bundibugyo virus disease (BVD) , in receipt of WHO
Emergency Use Listing).
Manufacturing Type:
i) The Qualifying Vaccine is Fully Manufactured on the African
continent;
or
ii) Fill & Finish of the Qualifying Vaccine is carried out in a
manufacturing facility on the African continent that is Controlled
by the holder of the WHO Pre- Qualification of the Qualifying
Vaccine.

Procurement
pathway Via successful Gavi
-UNICEF tenders and fulfil all other eligibility criteria
A potential AU pooled procurement mechanism may be accommodated in
the future, subject to determination in line with AVMA’s governance
arrangements)

06b Annex B Allocation methodology and partner ceilings pdf



Board-2026-Mtg -02-Doc 06b-Annex B 1
Report to the Board
1-2 July 2026
Annex B: Ecosystem Support — Allocation methodology and partner ceilings
This annex presents the allocation outcomes, following the Independent Review
Committee's (IRC) review (see Appendix 1 ) of the joint partner proposal for the AVMA+
Ecosystem Support Window (see Appendix 2). It presents IRC endorsed methodology
the Secretariat has applied to translate IRC ratings into indicative per -partner ceilings,
and the resulting funded and not -funded workstreams.
1. The IRC's assessment
The joint proposal was reviewed by the IRC against eight assessment criteria: Risk
Framework mapping, Theory of Change, Results Framework and Measurability,
Additionality and Non -Duplication, Mode of Delivery and Readiness, Institutional
Capacity, Budget Q uality and Realism, and Value for Money. The IRC produced an
overall alignment rating (High, Medium, or Low) for each partner on each AVMA risk
that partner addressed.
The matrices below set out the IRC's per -cell ratings. Figure 1a covers the three high-
priority risks where the substantive funding decisions are concentrated. Figure 1b
covers the medium - and lower -priority risks. The table in Section 4 provides a key to
the Risk codes, which are elaborated further in Appendix 3: AVMA Risk Management
Framework .

Figure 1a. IRC alignment ratings — HIGH-priority risks (A.3, D.7, B.2).

07 Annex A Financial Forecast additional details as of 18 June pdf



Board-2026-Mtg -02-Doc 07-Annex A 1
Report to the Gavi Board
1-2 July 2026
Annex A: Financial Forecast Additional Information

1. Gavi 6.0 prior forecast (v23) restatement
1.1. The v23 ( December 2025 Board) expenditure forecast has been restated to
present Catalytic Phase and Fragile & Humanitarian approach costs allocated
against the relevant vaccine and cash programmes (where previously these
were reported as single- line envelopes, under cash programmes).

Figure 1: restatement of prior forecast

2. Gavi 6.0 v23.2 financial forecast: Consolidated financial view
2.1. The ‘Gavi 6.0’ forecast has been prepared in line with the Board approved
strategy and resources / expenditure envelopes of US$ 10.2 billion (including
AVMA+, subject to Board approval) . In addition, the Secretariat has prepared
updated projections of expenditures for the 2026- 2030 period for other
programmes, including the African Vaccine Manufacturing Accelerator (AVMA),
the Pandemic Prevention Preparedness and Response (PPPR) Coalition, the
First Response Fund (FRF) and legacy COVAX Advance Market Commit ment

07 Annex A Financial Forecast additional details pdf



Board-2026-Mtg -02-Doc 07-Annex A 1
Report to the Gavi Board
1-2 July 2026
Annex A: Financial Forecast Additional Information

1. Gavi 6.0 prior forecast (v23) restatement
1.1. The v23 ( December 2025 Board) expenditure forecast has been restated to
present Catalytic Phase and Fragile & Humanitarian approach costs allocated
against the relevant vaccine and cash programmes (where previously these
were reported as single- line envelopes, under cash programmes).

Figure 1: restatement of prior forecast

2. Gavi 6.0 v23.2 financial forecast: Consolidated financial view
2.1. The ‘Gavi 6.0’ forecast has been prepared in line with the Board approved
strategy and resources / expenditure envelopes of US$ 10.2 billion (including
AVMA+, subject to Board approval) . In addition, the Secretariat has prepared
updated projections of expenditures for the 2026- 2030 period for other
programmes, including the African Vaccine Manufacturing Accelerator (AVMA),
the Pandemic Prevention Preparedness and Response (PPPR) Coalition, the
First Response Fund (FRF) and legacy COVAX Advance Market Commit ment

08 Annex A Gavi Alliance Risk Appetite Statement version 4 0 pdf

Gavi Alliance Risk
Appetite Statement
JULY 2026  VERSION 4.0Doc 08 - Annex A
Cover image credit: Gavi/2026
Document administration
Version number Approval processDate
1.0 Reviewed and recommended by: Gavi Programme & Policy Committee 10 November 2014
Approved by: Gavi Alliance Board 11 December 2014
2.0 Reviewed and recommended by: Gavi Audit & Finance Committee27 April 2017
Approved by: Gavi Alliance Board 15 June 2017
3.0 Reviewed and recommended by: Gavi Audit & Finance Committee7 June 2021
Approved by: Gavi Alliance Board 23 June 2021
3 .1 Reviewed and recommended by: Gavi Audit & Finance Committee17 October 2023
Approved by: Gavi Alliance Board 6–7 December 2023
4.0 Reviewed and recommended by: Gavi Audit & Finance Committee4 June 2026
Approved by: Gavi Alliance Board 1–2 July 2026
Effective from: 2 July 2026
Next review: As and when requested
02Doc 08 - Annex A

09 Annex A Risks and Mitigations pdf



Board-2026- Mtg-02-Doc 09-Annex A

Report to the Board
1-2 July 2026
Annex A : Risk implication and mitigation including for countries and the Alliance 
This annex outlines the risks and proposed mitigation measures associated with the
implementation of the Vaccine Budget Policy . The risks and mitigations are based on
Gavi Secretariat analysis and consultations with Alliance partners and countries.
Key risks and mitigation measures are outlined in the table below:  
Risk    Mitigation measures  
Country Financial & Implementation Risks
Countries not making a formal decision
to discontinue existing programmes
but delaying co-financing payments
and entering into default for specific
programmes .
Country communication to underscore and explain the
implications of the Vaccine Budgets (VB) and
allocating additional funding if available .
Unpredictable or inaccurate demand
leading to underfunding or stock -outs .
VBs represent Gavi?s best understanding of country
demand. The methodology reflects the demand
forecast for programmes under guaranteed budgets,
which offers a good level of accuracy of the needs of
countries especially for ongoing programmes. The
budgets are less accurate for N ew Vaccine
I ntroductions (NVIs) and preventative campaigns,
however the aim is to ensure predictable funding for
countries . Where new funding needs arise they will be
considered through the annual review mechanism and
prioritised according to the prioritisation logic.
Increased burden on country domestic
resources (self-financing in addition to
co -financing) .
The cumulative impact of the Gavi 6.0 changes to
Gavi?s operating model ( Eligibility and Transition, and
Co -financing Policies , VBs, campaign co -financing) is
reflected in higher requirements for domestic resource
investments in immuni sation, where those resources
may not be available. The VB design has Initial Self -
Financing ( ISF) country
floors that ensure these
countries do not need to self - finance their existing
programmes. The design has also considered the
need for self-financing in Accel erated Transition ( AT)
and Preparatory Transition (PT ) countries and
minimised it in discretionary budget
allocations to
balance out the impact across PT and AT countries
whose VB is expected to not fully meet the costs of
ongoing programmes. The policy also introduces the
possibility for countries to self -finance portions of their
programmes and not t he complete programme with
the possibility of reinvesting in another programme,
while other innovative financing options are being
made available to countries through the Mu ltilateral
Development Bank ( MDB) multiplier.

09 Annex B Vaccine Budget Policy clean version pdf




Board-2026- Mtg-02-Doc 09-Annex B

Classified as Internal
Report to the Board
1 -2 July 2026
Gavi Alliance
Va ccine Budget Policy
Version 1.0





DOCUMENT ADMINISTRATION


VERSION
NUMBER APPROVAL PROCESS DATE
1.0
Prepared by: Ombline Richard,
Head, Policy

Reviewed by: Gavi P rogramme and
Policy Committee

Approved by: Gavi Alliance Board

13 May 2026


TBD
Effective from: 3 July 2026
Next review: As and when required




2
Board -2026- Mtg-02-Doc 09-Annex B

Classified as Internal
Gavi Alliance
Vaccine Budget Policy
1. Scope and purpose
1.1. This policy defines the rules for the allocation of funding through c ountry-specific
Vaccine Budget s.
• The Vaccine Budget s appl y to Gavi -eligible countries
1, as outlined in the Gavi
F unding Guidelines , for funding over one five -year strategic period.
• It applies to the procurement of Gavi -supported vaccines , devices and freight.
1.2. The policy does not apply to Gavi support for emergencies, outbreaks or
diagnostics .
1.3. This policy should be considered together with the Eligibility and Transition Policy,
Co -financing Policy and the Health Systems and Immunisation Strengthening
(HSIS) Policy .
1.4. The objectives of the policy are to:
• Maximise health impact and value for money ,
• Minimise risk of outbreaks ,
• Ensure equitable access to vaccines ,
• Improve financial and programmatic sustainability , and
• Protect market health.
1.5. The following principles guide the design and implementation of the Vaccine
Budget policy:
• Flexibility for countries: Ensure countries have flexibility and decision-
making autonomy to manage trade- offs within their allocated budget.
• Continuity of support : Minimise disruptions of existing vaccine programmes
already introduced by countries.
• Simplicity : Ensure predictability of funding for countries and operational
feasibility.
2. Definitions
• Vaccine Budget : Country -specific allocations provided to Gavi -eligible
countries for their vaccine procurement support over a five -year strategic
period, made up of two components , guaranteed and discretionary, and subject
to updates through review of allocations and the prioritisation process .
• Initial Self -F inancing (ISF) Floor: Vaccine Budget s for ISF countries include
enough support to ensure continuity of their existing vaccine programmes that
fall under the discretionary budget and to ensure malaria vaccine scale- up and
new malaria vaccine introductions in up to 70% of moderate - to high-
transmission areas.

1 Catalytic phase countries also receive funding from the total allocation for Vaccine Budgets per
the funding guidelines but are not subject to this policy.

09 Annex C Vaccine Budget Policy marked up version from PPC version pdf




Board -2026 -Mtg -02-Doc 09 -Annex C

Report to the Board
1 - 2 July 2026
Classified as Internal
Gavi Alliance
Va ccine Budget Policy
Version 1.0





DOCUMENT ADMINISTRATION


VERSION
NUMBER APPROVAL PROCESS DATE
1.0
Prepared by: Ombline Richard,
Head, Policy

Reviewed by: Gavi P rogramme and
Policy Committee

Approved by: Gavi Alliance Board

13 May 2026


TBD
Effective from: 3 July 2026
Next review: As and when required





2
Board -2026 -Mtg -02-Doc 09 -Annex C

Gavi Alliance
Vaccine Budget Policy
Classified as Internal
1. Scope and p urpose
1.1. This policy defines the rules for the allocation of funding through c ountry -specific
Vaccine Budget s.
• The Vaccine Budget s appl y to Gavi -eligible countries 1, as outlined in the Gavi
Funding Guidelines , for funding over one five -year strategic period.
• It applies to the procurement of Gavi -supported vaccines , devices and freight.
1.2. The policy does not apply to Gavi support for emergencies, outbreaks or
diagnostics .
1.3. This policy should be considered together with the Eligibility and Transition Policy ,
Co -financing Policy and the Health Systems and Immunisation Strengthening
(HSIS) Policy .
1.4. The objectives of the policy are to :
• Maximise health impact and value for money ,
• Minimise risk of outbreaks ,
• Ensure equitable access to vaccines ,
• Improve financial and programmatic sustainability , and
• Protect market health .
1.5. The following principles guide the design and implementation of the Vaccine
Budget policy:
• Flexibility for countries : Ensure countries have flexibility and decision -
making autonomy to manage trade -offs within their allocated budget.
• Continuity of support : Minimise disruptions of existing vaccine programmes
already introduced by countries.
• Simplicity : Ensure predictability of funding for countries and operational
feasibility.
2. Definitions
• Vaccine Budget : Country -specific allocations provided to Gavi -eligible
countries for their vaccine procurement support over a five -year strategic
period , made up of two components , guaranteed and discretionary, and subject
to updates through review of allocation s and the prioritisation process .
• Initial Self -Financing (ISF) Floor: Vaccine Budget s for ISF countries include
enough support to ensure continuity of their existing vaccine programmes that
fall under the discretionary budget and to ensure malaria vaccine scale -up and
new malaria vaccine introductions in up to 70% of moderate - to high -
transmission areas.

1 Catalytic phase countries also receive funding from the total allocation for Vaccine Budgets per
the funding guidelines but are not subject to this policy.